Company Encyclopedia
View More
name
Daxor
DXR.US
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
1.407 T
DXR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking91/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.26%C
    • Profit Margin2710.84%A
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-57.00%E
    • Net Profit YoY6.55%C
    • Total Assets YoY4.44%C
    • Net Assets YoY9.10%B
  • Cash ScoreD
    • Cash Flow Margin3.69%C
    • OCF YoY-57.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio0.76%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Daxor (NASDAQ:DXR) Trading Down 1.2% - Should You Sell?

    Daxor Corporation (NASDAQ:DXR) shares fell 1.2% during mid-day trading on Wednesday, with the stock trading as low as $12.60. Trading volume was significantly lower than average. Analysts have given the stock a Moderate Buy rating with a target price of $25.00. Institutional investors own 1.34% of the company's stock. Daxor specializes in blood volume measurement technology. Despite the recent dip, analysts suggest considering other stocks for better investment opportunities.

    Market Beat·
    US
    DXR
    +1.58%
    Market Beat·
    US
    DXR
    +1.58%

    Daxor Corporation Files Initial Statement of Beneficial Ownership for Chief Medical Officer John Jefferies

    Daxor Corporation has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission, listing Chief Medical Officer John Jefferies as the beneficial owner. The filing is accessible through the SEC's EDGAR system. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    DXR
    +1.58%
    Reuters·
    US
    DXR
    +1.58%

    Daxor Corporation (NASDAQ:DXR) Short Interest Down 42.2% in July

    Daxor Corporation (NASDAQ:DXR) experienced a 42.2% decrease in short interest in July, with totals dropping from 10,900 shares to 6,300 shares by July 31st. The days-to-cover ratio is currently 0.2 days, with approximately 0.3% of shares sold short. Daxor's stock opened at $10.60, with a 12-month range of $6.55 to $11.38. Institutional investor Renaissance Technologies LLC increased its holdings by 87.7%, owning 27,821 shares worth $214,000. Daxor specializes in blood volume measurement technology.

    Market Beat·
    US
    DXR
    +1.58%
    Market Beat·
    US
    DXR
    +1.58%

    Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

    Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision ...

    GlobeNewswire·
    US
    DXR
    +1.58%
    GlobeNewswire·
    US
    DXR
    +1.58%

    FDA approves new blood volume analysis system by Daxor Corp, fast tracking medical advancements.

    FDA has approved a new blood volume analysis system developed by Daxor Corp, which is expected to accelerate advancements in medical technology. Additionally, the unemployment rate in the country has decreased to 4.5%, the lowest in a decade, with 250,000 new jobs created last quarter and average wages rising by 3.2%. Government officials view these statistics as indicators of a strengthening economy and are optimistic about future growth.

    Unusual Whales·
    US
    DXR
    +1.58%
    Unusual Whales·
    US
    DXR
    +1.58%
    © 2025 Longbridge｜Disclaimer